Seeking Alpha

Justin M. Hall's  Instablog

Justin M. Hall is an entrepreneur, investor and author. Hall serves as owner and founder of HiRx, LLC located in Indianapolis, Indiana. He is the author of "The Option Investors Desk Reference©" (2008). Hall invests in areas of innovative growth, such as (1) late-stage drug, device... More
My blog:
SeekingAlpha Instablog
  • Fuel Systems & Three Cancer Drug Makers 2 comments
    Aug 24, 2009 07:26 PM | about stocks: FSYS, ONTY, TOMO, SUPG, ARIA, SWC, CLNE, ONB, GTXI, SPPI, PRXL, OSIR, UNG
    The Lucky 13 Buys portfolio was introduced on July 7, 2009. In less than two months, this portfolio of carefully selected companies has gained nearly 30%. Three of the companies have achieved gains of greater than 53%. While almost ½ are up over 38%, more than ¾ of the Lucky 13 have advanced more than 15%.
     
    Since the Lucky 13 Buys debuted, several leaders have emerged and since pulled back from their respective highs. To view past results, click on the companies listed below.

    LUCKY 13 BUYS

    Symbol
    Last
    Gain/Loss (%)
    FSYS
    32.20
    72.93%
    ONTY
    5.32
    65.74%
    TOMO
    4.05
    53.41%
    SUPG
    2.89
    42.36%
    ARIA
    2.12
    40.40%
    SWC
    7.01
    38.26%
    CLNE
    10.62
    23.34%
    ONB
    11.15
    19.00%
    GTXI
    9.61
    18.50%
    SPPI
    6.49
    15.28%
    PRXL
    12.98
    2.77%
    OSIR
    12.25
    (-2.23%)
    UNG
    11.35
    (-6.81%)
    Portfolio
    Gain
     
    +29.48%
    Data: Closing prices from July 7 to August 21, 2009.
     
    FUEL SYSTEM SOLUTIONS
    Fuel System Solutions (FSYS), the newest leader of the Lucky 13, has gained nearly 73% in the past seven weeks. On Thursday, August 6, FSYS reported solid Q2 2009 earnings which beat analysts’ estimates. Eight days later, on August 14, Jim Cramer, the host of CNBC’s Mad Money, provided a favorable outlook on the company. 
     
    FSYS is one of three plays, within the Lucky 13, on T. Boone Pickens’ Plan. Under the Pickens’ Plan, Boone has proposed a solution that could enable the US to reduce its dependence on foreign oil by shifting commercial vehicles from diesel and gasoline to a much cleaner and cheaper (for now) natural gas – compressed (CNG) or Liquid (LNG). According to Boone, even former US Vice-President Al Gore likes the idea! It is worth noting a bill could be passed as early as this year calling for half of the federal government’s fleet to be switched from petroleum-based fuels over to natural gas. If so, this would likely spell a huge win for FSYS. 

    Interested investors ought to keep an eye on FSYS.
     
    OTHER RECENT CALLS
    • On August 17, 2009, I alerted investors at my SeekingAlpha blog that SPPI Is a Buy at $6.12 when shares retested their 50-day MA. In four short days, SPPI advanced +6.05% to close at $6.49 on Friday, August 21.



    • On August 14, 2009, I pointed out that ARIA had Significant Catalysts Approaching. Since then, ARIA has jumped +17.78%. At the end of last week’s trading, shares of the stock closed at $2.12.



    • On July 14, 2009, I wrote that SPPI was Oversold and Undervalued at $4.98. Since that time, shares have advanced +30.32%.
     
    GOING FOWARD    
    Some on Wall Street are expecting the market to pullback in the near-term. As major indices continue to post new highs (YTD), investors should -- at least -- anticipate and be prepared for stocks to retreat at some point in the near future.
     
    Throughout 2009, small cap drug makers with late stage products have been a good bet. Over the coming weeks and months, this trend is highly likely to continue. From my view, the best plays are late-stage drug makers with pending catalysts. Listed below are three of my favorite fall ‘09 picks (arranged by date of event).
     
    (1) Spectrum Pharmaceuticals (SPPI)
    On or before September 7, the FDA will review the company's non-Hodgkin's lymphoma drug, Zevalin® for first-line consolidation treatment. 
    On October 8, regulators are also scheduled to review SPPI's drug Fusilev® which is indicated for colorectal cancer.  For more details, see this August 20 article on SPPI.
     
    (2) Ariad Pharmaceuticals (ARIA)
    On or before September 30, data is expected from the first of two interim analyses of a Phase 3 study on ridaforolimus, an mTOR inhibitor that is indicated for soft-tissue and bone sarcomas.  For more details, see this August 14 article on ARIA.
     
    (3) GTX Inc. (GTXI)
    On October 30, regulators are also scheduled to review GTXI's new drug Acapodene® which is indicated for the treatment of bone loss in men with prostate cancer.

     
    Disclosure: Long ARIA and SPPI.
    Themes: Healthcare, Drug Manufacturers, Biotech, Long Ideas, Small Caps, Natural Gas Stocks: FSYS, ONTY, TOMO, SUPG, ARIA, SWC, CLNE, ONB, GTXI, SPPI, PRXL, OSIR, UNG
Back To Justin M. Hall's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

This post has 2 comments:

  •  
    Strengthened my position sppi on the dip let's roll
    Aug 24 11:36 PM | Link | Reply
  •  
    Nice work!
    Aug 25 06:38 AM | Link | Reply
Full index of posts »
Latest Followers
Posts by Ticker

Latest Comments


Most Commented
  1. Update: 10.9.09 (46 Comments)
  2. FULL DISCLOSURE STATEMENT (18 Comments)
  3. Spectrum Pharmaceuticals: Undervalued and [now] Oversold (17 Comments)
  4. Spectrum Pharmaceuticals: $50 Million Vote of Confidence or Cause for Concern (15 Comments)
  5. A NECESSARY COMPROMISE (14 Comments)
Posts by Themes
Are You Paying Attention, Are You Paying Attention , ASH 2009, Biotech, biotech, Biotech , Biotech Diagnosis, Biotech Equipment, Biotech Research, biotechnology, Cancer Drugs, Charlie Heidenreich, Charlie Heidenreich’s first article, China, Clean Energy, DJ HERO, Drug Makers, drug makers, Drug Manufacturers, Drug Manufacturers , Emerging Markets, ETF, ETFs, FULL DISCLOSURE STATEMENT, Gold, Healthcare, Industrials, Intelius, Long Ideas, Lucky 13 Buys, Lucky 13 Buys 2.0, Lucky 13 Buys 2.0 , Mergers Acquisitions, Mining, More Potential Buys List, N-95 Respirator Masks, Natural Gas, Options, pharmaceutical, Pharmaceutical, pharmaceuticals, Precious Metals, Regional Banks, Results, Short Ideas, Small Cap, small cap, Small Caps, Small-Cap, Specialty ETFs,
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.